San Diego’s MabVax Therapeutics Holdings Inc. has hired Dr. Paul Resnick for the newly created position of vice president and chief business officer.

In his role, Resnick will be responsible for corporate developing, including engaging big pharma and biotech companies on potential licensing and collaboration agreements for the company’s products, according to a MabVax news release.

Resnick comes from Juventas Therapeutics, where he served as senior vice president responsible for business and commercialization strategy. Previously, he held an executive position at Intellikine (acquired by Takeda Pharmaceuticals in a deal worth $310 million), and director positions at Pfizer and Roche, among others.

"Paul has a strong business and corporate development background with an excellent track record of success,” said president and CEO David Hansen in a statement. “We expect that he will be able to substantially enhance our corporate development efforts.”

MabVax is a clinical-stage biotechnology company focused on the development of antibody-based products and vaccines to address unmet medical needs in the treatment of cancer.